ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF
Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of the following randomized open label trial is to demonstrate how low
immunological risk patients (no anti HLA immunization and first kidney transplantation) but
diagnosed at high-risk of delayed graft function (assessed by DGFS score) could benefit from
induction with ATG for preventing delayed graft function compared to Basiliximab.